search

Active clinical trials for "Carcinoma, Non-Small-Cell Lung"

Results 121-130 of 5094

A Study of BMS-986340 as Monotherapy and in Combination With Nivolumab or Docetaxel in Participants...

Cervical CancerGastric/Gastroesophageal Junction Adenocarcinoma10 more

The purpose of this study is to assess the safety, tolerability, and recommended dose(s) of BMS-986340 as monotherapy and in combination with nivolumab or docetaxel in participants with advanced solid tumors. This study is a first-in-human (FIH) study of BMS-986340 in participants with advanced solid tumors.

Recruiting18 enrollment criteria

Plinabulin in Combination With Radiation/Immunotherapy in Patients With Select Advanced Cancers...

Advanced Bladder CarcinomaAdvanced Lung Non-Small Cell Carcinoma33 more

This phase Ib/II trial studies the side effects and best dose of plinabulin in combination with radiation therapy and immunotherapy in patients with select cancers that have spread to other places in the body (advanced) after progression on PD-1 or PD-L1 targeted antibodies. Plinabulin blocks tumor growth by targeting both new and existing blood vessels going to the tumor as well as killing tumor cells. Immunotherapy may induce changes in body's immune system and may interfere with the ability of tumor cells to grow and spread. Radiation therapy uses high energy x-rays to kill tumor cells and shrink tumors. Giving plinabulin in combination with radiation therapy and immunotherapy may work better in treating advanced cancers.

Recruiting50 enrollment criteria

Vactosertib in Combination With Pembrolizumab for PD-L1 Positive Non-small Cell Lung Cancer (NSCLC)...

CarcinomaNon-Small-Cell Lung

This is Phase 2, open label, multi-center study to assess safety and efficacy of vactosertib in combination with pembrolizumab as 1st line treatment for subjects with advanced or metastatic, PD-L1 positive, non-small cell lung cancer (NSCLC) who have not previously received systemic therapy for advanced disease and in whom EGFR, ALK, BRAF, ROS1-directed therapy is not indicated.

Recruiting16 enrollment criteria

Study BT8009-100 in Subjects With Nectin-4 Expressing Advanced Malignancies

Advanced Solid TumorUrinary Bladder Neoplasm4 more

This study is a Phase I/II, multicenter, first-in-human, open-label dose-escalation study of BT8009 given as a single agent and in combination with pembrolizumab in participants with advanced solid tumors associated with Nectin-4 expression or in participants with advanced solid tumor malignancies having renal insufficiency. The primary endpoints are Dose limiting toxicities (Parts A-1 and A-2), Overall response rate per RECIST v1.1 (Part B) and Safety and tolerability (Part C).

Recruiting32 enrollment criteria

Camrelizumab With Chemotherapy in Adults With Medically Inoperable Early Stage NSCLC

Early Stage Non-small Cell Lung Cancer

The purpose of this study is to assess the efficacy and safety of Camrelizumab plus chemotherapy in the treatment of adult participants with medically inoperable Stage I or IIA non-small cell lung cancer (NSCLC).

Recruiting27 enrollment criteria

Effect of Perioperative Bronchodilator in COPD Patients Undergoing Lung Cancer Surgery

Chronic Obstructive Pulmonary DiseaseNon Small Cell Lung Cancer

This is a double-blind randomized controlled trial evaluating the effect of perioperative dual bronchodilator therapy on post-operative pulmonary function and health-related quality of life (QoL) in mild-to-moderate less symptomatic COPD patients undergoing lung cancer surgery. Investigators hypothesized that dual bronchodilator, as compared with placebo, would prevent reduction of pulmonary function after surgical resection and improve postoperative health related QoL.

Recruiting13 enrollment criteria

Durvalumab and Tremelimumab in Combination With Chemotherapy in Virus-infected Patients With Non-small...

CarcinomaNon-Small Cell Lung

This is a phase II trial of durvalumab and tremelimumab in combination of platinum-based chemotherapy. Patients with stage IV Non-Small-Cell-Lung Cancer (NSCLC) with human immunodeficiency virus (HIV) infection (cohort 1) or hepatitis B virus (HBV), or hepatitis C virus (HCV) infection (cohort 2) will be eligible. Patients will receive standard platinum-based chemotherapy plus durvalumab for 4 cycles (every 3 weeks), followed by durvalumab (with or without pemetrexed for non-squamous NSCLC) maintenance therapy. It is hypothesized that Durvalumab and tremelimumab in combination with standard chemotherapy is safe and effective for the treatment of stage IV NSCLC in patients with HIV, HBV, or HCV infection.

Recruiting47 enrollment criteria

An Exploratory Study of Atezolizumab and Bevacizumab in Hepatocellular Carcinoma and Non-Small Cell...

Hepatocellular CarcinomaNon-small Cell Lung Cancer Metastatic1 more

This study is being done to look at how effective the drug, atezolizumab, with or without the drug bevacizumab, is for people with inoperable liver cancer or non-small lung cancer that has spread to the liver. This will be done by looking at the duration of time from starting the study drug(s) until the cancer worsens in study participants. This study will collect blood and tumor tissue samples from participants to look at changes to their tumor(s) before and after receiving atezolizumab and/or bevacizumab.

Recruiting54 enrollment criteria

A Phase Ib/II Clinical Trial to Evaluate the Safety and Efficacy of HLX208+HLX10 in NSCLC With BRAF...

Non Small Cell Lung Cancer

An open-label, multicenter phase Ib/II clinical study to evaluate safety, tolerability, pharmacokinetics, and efficacy of HLX208 (BRAF V600E Inhibitor) combined with HLX10 (anti-PD-1 monoclonal antibody)in advanced NSCLC patients with BRAF V600 mutation.

Recruiting30 enrollment criteria

A Study of BMS-986442 With Nivolumab With or Without Chemotherapy in Solid Tumors and Non-small...

Advanced Solid TumorsNon-small Cell Lung Cancer

The purpose of this study is to evaluate BMS-986442 in combination with nivolumab (with or without chemotherapy) for its antitumor efficacy and benefit to participants.

Recruiting7 enrollment criteria
1...121314...510

Need Help? Contact our team!


We'll reach out to this number within 24 hrs